SOURCE-LINKED STUDY SUMMARY
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind randomized trial compared tesamorelin with placebo for six months. Primary outcomes were visceral abdominal fat and liver fat.
- Who / model studied
- 50 adults with HIV receiving antiretroviral treatment and with abdominal-fat accumulation were randomized; forty-eight received study treatment.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Visceral-fat area fell by 34 square centimeters with tesamorelin versus an increase of 8 with placebo. The liver lipid-to-water percentage fell 2.0 percentage points versus a 0.9-point increase. Fasting glucose rose initially at two weeks, but six-month fasting and two-hour glucose changes did not significantly differ.
- Limitations & context
- The authors described the findings as preliminary and said further studies were needed to determine their clinical importance and long-term consequences.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2014.8334